Phase I, Open-label, Multi-center, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Activity of CH5132799 Administered Orally as a Monotherapy in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2014
At a glance
- Drugs CH 5132799 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chugai Pharma Europe
- 14 Oct 2014 Top-line results reported in a Chugai Pharma media release.
- 20 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.